Mohammadi Mehrdad, Shohani Amin, Khorami Hatef, Nouri Mahdavi Kia, IzadPanahi Mohammad Hossein, Alizadeh Farshid, Azizi Mohammad
Isfahan Kidney Transplantation Research Center, Department of Urology, Alzahra Research Centers, Isfahan University of Medical Science, Isfahan, Iran.
Biomedicine (Taipei). 2018 Dec;8(4):26. doi: 10.1051/bmdcn/2018080426. Epub 2018 Nov 26.
Cystinuria as an autosomal recessive sickness is a relatively rare disease. Formation of cystine stones indicates cystinuria. Few studies are considered the cysteine crystal volume in management of cystinuria. Selenium may inhibit organization of crystal stone, growth and stone aggregation. Since the role of selenium on inhibition of cystine crystal formation is not known, the aim of this study was to evaluate the effect of selenium supplementation on cystine crystals volume in patients with cystinuria.
This double-blind clinical trial study was conducted on 48 patients in Al-Zahra hospital, Isfahan, Iran from 2015 to 2017. These patients received selenium (200 mg/ daily) for 6 weeks. The urine crystal volume was evaluated before and after treatment. Data were entered SPSS and analyzed by Paired sample T test, Spearman and Pearson coefficient correlation. P- value < 0.05 was considered significant.
In current study, mean cystine crystal volume before and after treatment was 6787.4 ± 11902.6 and 3110.9 ± 7225.4, respectively. Significant difference was observed before and after treatment in terms of cystine crystal volume (p < 0.001). No relation was observed between the mean cystine crystal volume with sex, age and type of medical procedures (p > 0.05).
In this study, selenium treatment affected cystine crystal volume. It seems that selenium had the potential value to alleviate the volume of cystine crystal. Therefore, since reducing of cystine crystal volume decreases crystal formation, selenium may be effective to cure patients with cystinuria. However, age, sex and type of medical procedures did not affect cysteine crystal volume.
胱氨酸尿症作为一种常染色体隐性疾病，是一种相对罕见的疾病。胱氨酸结石的形成表明患有胱氨酸尿症。很少有研究在胱氨酸尿症的治疗中考虑半胱氨酸晶体体积。硒可能抑制晶体结石的形成、生长和结石聚集。由于硒对抑制胱氨酸晶体形成的作用尚不清楚，本研究的目的是评估补充硒对胱氨酸尿症患者胱氨酸晶体体积的影响。
这项双盲临床试验研究于2015年至2017年在伊朗伊斯法罕的扎赫拉医院对48名患者进行。这些患者接受了6周的硒（每日200毫克）治疗。在治疗前后评估尿晶体体积。数据录入SPSS并通过配对样本T检验、Spearman和Pearson系数相关性进行分析。P值<0.05被认为具有显著性。
在本研究中，治疗前后的平均胱氨酸晶体体积分别为6787.4±11902.6和3110.9±7225.4。在胱氨酸晶体体积方面，治疗前后观察到显著差异（p<0.001）。平均胱氨酸晶体体积与性别、年龄和医疗程序类型之间未观察到相关性（p>0.05）。
在本研究中，硒治疗影响了胱氨酸晶体体积。似乎硒具有减轻胱氨酸晶体体积的潜在价值。因此，由于减少胱氨酸晶体体积可减少晶体形成，硒可能对治疗胱氨酸尿症患者有效。然而，年龄、性别和医疗程序类型并未影响半胱氨酸晶体体积。
